首站-论文投稿智能助手
典型文献
Multicenter study of the clinicopathological features and recurrence risk prediction model of early-stage breast cancer with low-positive human epidermal growth factor receptor 2 expression in China (Chinese Society of Breast Surgery 021)
文献摘要:
Background::Breast cancer with low-positive human epidermal growth factor receptor 2 (HER2) expression has triggered further refinement of evaluation criteria for HER2 expression. We studied the clinicopathological features of early-stage breast cancer with low-positive HER2 expression in China and analyzed prognostic factors.Methods::Clinical and pathological data and prognostic information of patients with early-stage breast cancer with low-positive HER2 expression treated by the member units of the Chinese Society of Breast Surgery and Chinese Society of Surgery of Chinese Medical Association, from January 2015 to December 2016 were collected. The prognostic factors of these patients were analyzed.Results::Twenty-nine hospitals provided valid cases. From 2015 to 2016, a total of 25,096 cases of early-stage breast cancer were treated, 7642 (30.5%) of which had low-positive HER2 expression and were included in the study. After ineligible cases were excluded, 6486 patients were included in the study. The median follow-up time was 57 months (4-76 months). The disease-free survival rate was 92.1% at 5 years, and the overall survival rate was 97.4% at 5 years. At the follow-up, 506 (7.8%) cases of metastasis and 167 (2.6%) deaths were noted. Multivariate Cox regression analysis showed that tumor stage, lymphvascular invasion, and the Ki67 index were related to recurrence and metastasis (P < 0.05). The recurrence risk prediction model was established using a machine learning model and showed that the area under the receiving operator characteristic curve was 0.815 (95% confidence interval: 0.750-0.880). Conclusions::Early-stage breast cancer patients with low-positive HER2 expression account for 30.5% of all patients. Tumor stage, lymphvascular invasion, and the Ki67 index are factors affecting prognosis. The recurrence prediction model for breast cancer with low-positive HER2 expression based on a machine learning model had a good clinical reference value for predicting the recurrence risk at 5 years.Trial registration::ChiCTR.org.cn, ChiCTR2100046766.
文献关键词:
Breast tumor;Low-positive HER2 expression;Multicenter;CSBrS research;Recurrence risk prediction model
作者姓名:
Xin Ling;Wu Qian;Zhan Chongming;Qin Hongyan;Xiang Hongyu;Xu Ling;Ye Jingming;Duan Xuening;Liu Yinhua;Chinese Society of Breast Surgery (CSBrS);Chinese Society of Surgery of Chinese Medical Association
作者机构:
Breast Disease Center, Peking University First Hospital, Beijing 100034, China;Jun Yi Tai He Medical Technology Co. Ltd, Beijing 100024, China
引用格式:
[1]Xin Ling;Wu Qian;Zhan Chongming;Qin Hongyan;Xiang Hongyu;Xu Ling;Ye Jingming;Duan Xuening;Liu Yinhua;Chinese Society of Breast Surgery (CSBrS);Chinese Society of Surgery of Chinese Medical Association-.Multicenter study of the clinicopathological features and recurrence risk prediction model of early-stage breast cancer with low-positive human epidermal growth factor receptor 2 expression in China (Chinese Society of Breast Surgery 021))[J].中华医学杂志(英文版),2022(06):697-706
A类:
lymphvascular,ChiCTR2100046766,CSBrS
B类:
Multicenter,study,clinicopathological,features,recurrence,risk,prediction,model,early,stage,breast,cancer,positive,human,epidermal,growth,receptor,expression,China,Chinese,Society,Breast,Surgery,Background,HER2,has,triggered,further,refinement,evaluation,criteria,We,studied,analyzed,prognostic,factors,Methods,Clinical,data,information,patients,treated,by,member,units,Medical,Association,from,January,December,were,collected,these,Results,Twenty,nine,hospitals,provided,valid,cases,From,total,which,had,included,After,ineligible,excluded,median,follow,up,was,months,disease,free,survival,rate,years,overall,At,metastasis,deaths,noted,Multivariate,Cox,regression,analysis,showed,that,tumor,invasion,Ki67,related,established,using,machine,learning,area,under,receiving,operator,characteristic,curve,confidence,interval,Conclusions,Early,account,Tumor,affecting,prognosis,good,clinical,reference,value,predicting,Trial,registration,org,cn,Low,research,Recurrence
AB值:
0.429064
相似文献
Identification of hub genes and their novel diagnostic and prognostic significance in pancreatic adenocarcinoma
Duo Zuo;Yongzi Chen;Xinwei Zhang;Zhuozhi Wang;Wenna Jiang;Fan Tang;Runfen Cheng;Yi Sun;Lu Sun;Li Ren;Rui Liu-Department of Clinical Laboratory;Department of Tumor Cell Biology,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin,Tianjin's Clinical Research Center for Cancer,Tianjin 300060,China;School of Biomedical Engineering,Tianjin Medical University,Tianjin 300070,China;Department of Pathology,Tianjin Huanhu Hospital,Tianjin 300350,China;Department of Pathology,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin,Tianjin's Clinical Research Center for Cancer,Tianjin 300060,China;School of Pharmacy,Tianjin Medical University,Tianjin 300070,China;Department of Gastrointestinal Medical Oncology,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin,Tianjin's Clinical Research Center for Cancer,Tianjin 300060,China
Development and evaluation of the screening performance of a low-cost high-risk screening strategy for breast cancer
Yubei Huang;Huan Wang;Zhangyan Lyu;Hongji Dai;Peifang Liu;Ying Zhu;Fengju Song;Kexin Chen-Department of Cancer Epidemiology and Biostatistics,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy of Tianjin,Tianjin's Clinical Research Center for Cancer,Key Laboratory of Cancer Molecular Epidemiology of Tianjin,Key Laboratory of Breast Cancer Prevention and Therapy,Ministry of Education,Tianjin 300060,China;Department of Breast Imaging,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy of Tianjin,Tianjin's Clinical Research Center for Cancer,Key Laboratory of Cancer Molecular Epidemiology of Tianjin,Key Laboratory of Breast Cancer Prevention and Therapy,Ministry of Education,Tianjin 300060,China
Development and evaluation of a predictive nomogram for survival in heat stroke patients: a retrospective cohort study
Fei Shao;Xian Shi;Shu-hua Huo;Qing-yu Liu;Ji-xue Shi;Jian Kang;Ping Gong;Sheng-tao Yan;Guo-xingWang;Li-jie Qin;Fei Wang;Ke Feng;Feng-ying Chen;Yong-jie Yin;Tao Ma;Yan Li;Yang Wu;Hao Cui;Chang-xiao Yu;Song Yang;Wei Gan;Sai Wang;Liu-ye-zi Du;Ming-chen Zhao;Zi-ren Tang;Shen Zhao-Department of Emergency Medicine,Beijing Chaoyang Hospital,Capital Medical University,Beijing 100020,China;Department of Emergency Medicine,Hebei Yanda Hospital,Langfang 065201,China;Department of Emergency Medicine,Beijing Huairou Hospital,Beijing 101400,China;Department of Emergency Medicine,the Second Hospital of Hebei Medical University,Shijiazhuang 050000,China;Department of Emergency Medicine,the Second Affiliated Hospital of Shandong First Medical University,Tai'an 271000,China;Department of Emergency Medicine,the First Affiliated Hospital of Dalian Medical University,Dalian 116011,China;Department of Emergency Medicine,China-Japan Friendship Hospital,Beijing 100029,China;Department of Emergency Medicine,Beijing Friendship Hospital,Beijing 100050,China;Department of Emergency Medicine,Henan Provincial People's Hospital,Zhengzhou 450003,China;Department of Emergency Medicine,Beijing Tsinghua Changung Hospital,Beijing 102218,China;Department of Emergency Medicine,General Hospital of Ningxia Medical University,Yinchuan 750004,China;Department of Emergency Medicine,the Affiliated Hospital of Inner Mongolia Medical University,Hohhot 010050,China;Department of Emergency Medicine,the Second Hospital of Jilin University,Changchun 130021,China;Department of Emergency Medicine,the First Hospital of China Medical University,Shenyang 110001,China;Department of Emergency Medicine,the Second Hospital of Shanxi Medical University,Taiyuan 030001,China;Department of Big Data Research,Goodwill Hessian Health Technology Co.,Ltd.,Beijing 100085,China;School of Public Health,Peking University,Beijing 100083,China;Beijing Key Laboratory of Cardiopulmonary Cerebral Resuscitation,Beijing 100020,China;Department of Critical Care Medicine,Beijing Friendship Hospital,Capital Medical University,Beijing 100050,China
CT-based radiomics to predict development of macrovascular invasion in hepatocellular carcinoma:A multicenter study
Jing-Wei Wei;Si-Rui Fu;Jie Zhang;Dong-Sheng Gu;Xiao-Qun Li;Xu-Dong Chen;Shuai-Tong Zhang;Xiao-Fei He;Jian-Feng Yan;Li-Gong Lu;Jie Tian-Key Laboratory of Molecular Imaging,Institute of Automation,Chinese Academy of Sciences,Beijing 100190,China;Beijing Key Laboratory of Molecular Imaging,Beijing 100190,China;University of Chinese Academy of Sciences,Beijing 100049,China;Zhuhai Interventional Medical Center,Zhuhai Precision Medical Center,Zhuhai People's Hospital,Zhuhai Hospital of Jinan University,Zhuhai 519000,China;Department of Radiology,Zhuhai Precision Medical Center,Zhuhai People's Hospital,Zhuhai Hospital of Jinan University,Zhuhai 519000,China;Department of Interventional Treatment,Zhongshan City People's Hospital,Zhongshan 528400,China;Department of Radiology,Shenzhen People's Hospital,Shenzhen 518000,China;Interventional Diagnosis and Treatment Department,Nanfang Hospital,Southern Medical University,Guangzhou,510000,China;Department of Radiology,Yangjiang People's Hospital,Yangjiang 529500,China;Beijing Advanced Innovation Center for Big Data-Based Precision Medicine,School of Medicine and Engineering,Beihang University,Beijing 100191,China;Engineering Research Center of Molecular and Neuro Imaging of Ministry of Education,School of Life Science and Technology,Xidian University,Xi'an 710126,China
Clinical significance of serum IgM and IgG levels in COVID-19 patients in Hubei Province, China ☆
Bai Zhenjiang;Li Qing;Chen Qinghui;Niu Changming;Wei Yu;Huang Hanpeng;Zhao Wei;Chen Nian;Yao Xin;Zhang Qiang;Mu Chuanyong;Feng Jian;Zhu Chuanlong;Li Zhuo;Ding Ming;Feng Binhui;Jin Chaochao;Lu Xiang;Yang Yi;Wu Shuiyan;Shu Xiaochen;Hu Lifang;Qiu Haibo;Huang YingZi-Pediatric Intensive Care Unit, Children’s Hospital of Soochow University, Suzhou, Jiangsu 215025, China;Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, Jiangsu 210009, China;Department of Infectious Diseases, Children’s Hospital of Soochow University, Suzhou, Jiangsu 215025, China;Department of Critical Care Medicine, The Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210011, China;Department of Respirology, Jiangsu Province Hospital of TCM, Nanjing, Jiangsu 210046, China;Department of Respirology, Affiliated Hospital of Jiangsu University, Zhenjiang, Jiangsu 212001, China;Department of Critical Care Medicine, Sir Run Hospital Nanjing Medical University, Nanjing, Jiangsu 211112, China;Department of Infectious Diseases, The Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 211103, China;Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 211103, China;Department of Respirology, Southeast University Zhongda Hospital, Nanjing, Jiangsu 210009, China;Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, China;Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226019, China;Department of Emergency, Children’s Hospital of Nanjing Medical University, Nanjing, Jiangsu 210008, China;Department of Critical Care Medicine, Huangshi Central Hospital, Huangshi, Hubei 435002, China;Department of Oncology, Huangshi Hospital of TCM (Infectious Disease Hospital, Huangshi, Hubei 435002, China;Department of Geriatric Medicine, Sir Run Hospital Nanjing Medical University, Nanjing, Jiangsu 211112, China;Department of Epidemiology, School of Public Health, Medical College of Soochow University, Suzhou, Jiangsu 215031, China;Jiangsu Key Laboratory of Neuropsychiatric Diseases and Institute of Neuroscience, Soochow University, Suzhou, Jiangsu 215031, China
Prognostic and incremental value of computed tomography-based radiomics from tumor and nodal regions in esophageal squamous cell carcinoma
Bangrong Cao;Kun Mi;Wei Dai;Tong Liu;Tianpeng Xie;Qiang Li;Jinyi Lang;Yongtao Han;Lin Peng;Qifeng Wang-Radiation Oncology Key Laboratory of Sichuan Province Sichuan Cancer Hospital&Institute,Sichuan Cancer Center,School of Medicine,University of Electronic Science and Technology of China,Chengdu 610041,China;Department of Biobank Sichuan Cancer Hospital&Institute,Sichuan Cancer Center,School of Medicine,University of Electronic Science and Technology of China,Chengdu 610041,China;Department of Thoracic Surgery Sichuan Cancer Hospital&Institute,Sichuan Cancer Center,School of Medicine,University of Electronic Science and Technology of China,Chengdu 610041,China;Department of Medical Imaging Sichuan Cancer Hospital&Institute,Sichuan Cancer Center,School of Medicine,University of Electronic Science and Technology of China,Chengdu 610041,China;Department of Radiation Oncology,Sichuan Cancer Hospital&Institute,Sichuan Cancer Center,School of Medicine,University of Electronic Science and Technology of China,Chengdu 610041,China
Clinical value of next-generation sequencing in guiding decisions regarding endocrine therapy for advanced HR-positive/HER-2-negative breast cancer
Dan Lyu;Binliang Liu;Bo Lan;Xiaoying Sun;Lixi Li;Jingtong Zhai;Haili Qian;Fei Ma-Department of Medical Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Department of Breast Cancer Medical Oncology,Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University,Changsha 410013,China;Department of Medical Oncology,Cancer Hospital of Huanxing Chaoyang District,Beijing 100122,China;State Key Laboratory of Molecular Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China
Predictors of pathologic complete response in patients with residual flat mucosal lesions after neoadjuvant chemoradiotherapy for locally advanced rectal cancer
Changlong Li;Zhen Guan;Yi Zhao;Tingting Sun;Zhongwu Li;Weihu Wang;Zhexuan Li;Lin Wang;Aiwen Wu-Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Gastrointestinal Cancer Center,Peking University Cancer Hospital&Institute,Beijing 100142,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Radiology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Pathology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Radiation Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Cancer Epidemiology,Peking University Cancer Hospital&Institute,Beijing 100142,China
Adjuvant tamoxifen switched to exemestane treatment in postmenopausal women with estrogen receptor-positive early breast cancer: A pragmatic, multicenter, and prospective clinical trial in China
Binghe Xu;Huiping Li;Zefei Jiang;Lin Gu;Jinhai Tang;Hui Xie;Yueyin Pan;Yunjiang Liu;Shude Cui;Xiaojia Wang;Li Cai;Yiqiong Zhang;Huadong Zhao;Zhimin Shao-Department of Medical Oncology,National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),Department of Breast Oncology,Peking University Cancer Hospital&Institute,Beijing 100142,China;Department of Breast Cancer,the Fifth Medical Center of Chinese PLA General Hospital,Beijing 100071,China;Department of Breast Cancer,Tianjin Cancer Institute and Hospital,Tianjin 300060,China;Department of Breast Cancer,Jiangsu Provincial Hospital,Nanjing 210029,China;Department of Breast Cancer,the First Affiliated Hospital of China University of Science and Technology,Hefei 230001,China;Department of Breast Cancer,the Fourth Hospital of Hebei Medical University,Shijiazhuang 050011,China;Department of Breast Cancer,Henan Cancer Hospital,Zhengzhou 450008,China;Department of Breast Cancer,Zhejiang Cancer Hospital,Hangzhou 310012,China;Department of Breast Cancer,Harbin Medical University Cancer Hospital,Harbin 150081,China;Department of Clinical Development,Pfizer(China)R&D Co.Ltd,Shanghai 201203,China;Department of Statistics,Pfizer(China)R&D Co.Ltd,Shanghai 201203,China;Department of Breast Surgery,Shanghai Cancer Center/Cancer Institute,Shanghai Medical College,Fudan University,Shanghai 200032,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。